200 related articles for article (PubMed ID: 36970051)
1. CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy.
Cao A; Yi J; Tang X; Szeto CW; Wu R; Wan B; Fang X; Li S; Wang L; Wang L; Li J; Ye Q; Huang T; Hsu K; Kabbarah O; Zhou H
Cancer Res Commun; 2022 Nov; 2(11):1404-1417. PubMed ID: 36970051
[TBL] [Abstract][Full Text] [Related]
2. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
3. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
5. Targeting HDAC6 improves anti-CD47 immunotherapy.
Gracia-Hernandez M; Yende AS; Gajendran N; Alahmadi Z; Li X; Munoz Z; Tan K; Noonepalle S; Shibata M; Villagra A
J Exp Clin Cancer Res; 2024 Feb; 43(1):60. PubMed ID: 38414061
[TBL] [Abstract][Full Text] [Related]
6. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
7. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
8. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
[TBL] [Abstract][Full Text] [Related]
9. Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint.
Wu ZH; Li N; Mei XF; Chen J; Wang XZ; Guo TT; Chen G; Nie L; Chen Y; Jiang MZ; Wang JT; Wang HB
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256517
[TBL] [Abstract][Full Text] [Related]
10. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
11. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity.
Qu T; Zhong T; Pang X; Huang Z; Jin C; Wang ZM; Li B; Xia Y
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450383
[TBL] [Abstract][Full Text] [Related]
12. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
[TBL] [Abstract][Full Text] [Related]
13. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
[TBL] [Abstract][Full Text] [Related]
14. Extracellular Vesicles-Derived Hybrid Nanoplatforms for Amplified CD47 Blockade-Based Cancer Immunotherapy.
Tang L; Yin Y; Cao Y; Fu C; Liu H; Feng J; Wang W; Liang XJ
Adv Mater; 2023 Sep; 35(35):e2303835. PubMed ID: 37384818
[TBL] [Abstract][Full Text] [Related]
15. Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile.
Wang T; Wang SQ; Du YX; Sun DD; Liu C; Liu S; Sun YY; Wang HL; Zhang CS; Liu HL; Jin L; Chen XP
J Transl Med; 2024 Mar; 22(1):220. PubMed ID: 38429732
[TBL] [Abstract][Full Text] [Related]
16. Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.
Tian L; Xu B; Teng KY; Song M; Zhu Z; Chen Y; Wang J; Zhang J; Feng M; Kaur B; Rodriguez L; Caligiuri MA; Yu J
Clin Cancer Res; 2022 Jan; 28(1):201-214. PubMed ID: 34645647
[TBL] [Abstract][Full Text] [Related]
17. SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
Yu J; Li S; Chen D; Liu D; Guo H; Yang C; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Bai X; Song Y; Jiang Z; Zhang R; Tian W
J Hematol Oncol; 2022 Nov; 15(1):167. PubMed ID: 36384978
[TBL] [Abstract][Full Text] [Related]
18. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
[TBL] [Abstract][Full Text] [Related]
19. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
J Immunother Cancer; ; . PubMed ID: 32345627
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
